SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Dec. 31, 2023 USD ($) segment shares	Dec. 31, 2022 USD ($) shares
[custom:ResearchAndDevelopmentExpenseIncludingUSBasedClinicalTrialCost] | $	$ 3,300,000	$ 4,468,000
Significant Change in Unrecognized Tax Benefits, Nature of Event	the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising Expense | $	$ 426,000	$ 359,000
Weighted Average Number of Shares Outstanding, Diluted, Adjustment	9,612,502
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number	3,054,086	355,951
Number of Operating Segments | segment	1
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	74,978,006	2,741,355